FDA Panel Backs Novel Treatment for Postpartum Depression FDA Panel Backs Novel Treatment for Postpartum Depression

Vote was nearly unanimous that the benefits of brexanolone outweigh risks, but only when used within a strict Risk Evaluation and Mitigation Strategies (REMS) program.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Alert Source Type: news